Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Rhinitis Stories

2010-09-06 13:55:00

ANTONY, France, September 6, 2010 /PRNewswire-FirstCall/ -- Stallergenes S.A. has announced today the signing of exclusive partnership agreements with Shionogi & Co., Ltd. for two sublingual allergen immunotherapy tablet products resulting from the Stalair(R) program: Actair(R) house dust mite tablets and Japanese cedar pollen tablets. With 32 million respiratory allergy sufferers, there is a strong - and as yet unmet - demand for treatment in Japan, where sublingual allergen...

7ab7459b9a97d66fb5a5c3b446e3de371
2010-08-13 09:10:00

New evidence linking the use of acetaminophen to development of asthma and eczema suggests that even monthly use of the drug in adolescents may more than double risk of asthma in adolescents compared to those who used none at all; yearly use was associated with a 50 percent increase in the risk of asthma. The research results will be published online on the American Thoracic Society's Web site ahead of the print edition of the American Journal of Respiratory and Critical Care Medicine. "This...

2010-07-28 09:45:00

HORSHAM, Pa., July 28 /PRNewswire/ -- Teva Respiratory today announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to placebo. Furthermore, the safety profile of BDP HFA Nasal Aerosol was similar to placebo. "The outcomes of the...

2010-07-14 06:30:00

IRVINE, Calif., July 14 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it has initiated a Phase 1/2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group study will evaluate the safety and efficacy of three concentrations of bepotastine besilate, dosed twice daily, in an...

2010-07-09 15:39:00

AUSTIN, Texas, July 9 /PRNewswire/ -- Lake levels are higher and the normally brown Austin roadside is green and lush, but for allergy sufferers summer showers can increase their exposure to allergenic mold spores. Molds can be found inside and outside the home. Along with pollens from trees, grasses, and weeds, molds are an important trigger of allergic rhinitis, affecting nearly 40 million Americans, according to the American Academy of Allergy, Asthma & Immunology (AAAAI). "Mold...

2010-06-28 13:54:00

ANTONY, France, June 28, 2010 /PRNewswire-FirstCall/ -- After having announced positive results for the first year of its phase IIb/III clinical trial (VO 57.07) conducted on Actair(R) sublingual allergen immunotherapy tablets in allergic rhinitis triggered by house dust mites in April 2009, Stallergenes S.A. today announces the results of the second year of this study. Following this first year which demonstrated positive results for both the dosages tested (300 IR[1] and 500 IR)...

2010-06-24 03:59:33

Research shows Pycnogenol decreases nasal and ocular symptoms in allergic rhinitis patients An estimated 60 million people in the U.S. are affected by allergic rhinitis, commonly known as hay fever, according to the American Academy of Allergy Asthma and Immunology. Hay fever is an allergic inflammation of the nasal airways that causes itching, swelling, mucus production, hives and rashes. A study published in the June 14, 2010 issue of Phytotherapy Research demonstrates...

2010-06-21 01:46:00

ANTONY, France, June 21, 2010 /PRNewswire-FirstCall/ -- Stallergenes S.A. announces the results of a phase III clinical trial (VO55.06) conducted in China aimed at assessing the efficacy and safety of sublingual immunotherapy (Staloral(R) mites 300) in adult patients suffering from asthma triggered by house dust mites. Study VO55.06 is a phase III randomized, double-blind, placebo-controlled study conducted over a period of 15 months in 14 centers located in China's main cities....

2010-06-07 07:28:00

LONDON, June 7, 2010 /PRNewswire-FirstCall/ -- Data published at the European Allergy, Asthma & Clinical Immunology (EAACI) congress in London today documents that GRAZAX(R) is the only allergy immunotherapy tablet (AIT) to show sustained disease control 2 years after treatment completion. Leading specialists emphasise the relevance of the data with regard to inclusion in guidelines for treatment of grass pollen allergy. Traditional symptomatic medications, such as antihistamine...

2010-05-25 08:33:00

CARY, N.C., May 25 /PRNewswire/ -- Cetero Research, the leading early-stage contract research organization (CRO), announced today that it has more Environmental Exposure Chambers (EECs), or allergy models for recreating environmental conditions than any other CRO. Over the past nine years, Cetero has used these models in more than 40 clinical studies to help its pharmaceutical partners develop novel therapies for a wide range of anti-allergic small molecule drugs, immunotherapies,...